Table 4.
Theranostic radionuclides [19].
| Radionuclide | T1/2 (days) | Principal Eγ for Imaging, keV (%) | Therapeutic Particle(s) |
|---|---|---|---|
| Sc-47 | 3.35 | 159 (68) | β− |
| Cu-67 | 2.58 | 186 (40) | β− |
| Ga-67 | 3.26 | 93, 184, 296, (40, 24, 22) | Aug., C.E. |
| In-111 | 2.8 | 171, 245, (91, 94) | Aug., C.E. |
| Sn-117m | 14 | 159 (86) | C.E. |
| I-123 | 13.3 h | 159 (83) | Aug., C.E. |
| I-131 | 8 | 365 (82) | β− |
| Sm-153 | 1.94 | 103 (30) | β− |
| At-211 | 7.2 h | 79 (21) | α |
| Bi-213 | 46 min | 441 (926) | β−; α (from TI-209 → Bi-213 decay chain) |
β− = beta electrons; C.E.= conversion electrons; α = alpha particles; Aug. = Auger electrons.